Home › Burkitt Lymphoma › Illinois › Chicago

Pag-aaral pangklinika para sa Burkitt Lymphoma sa Chicago, IL

14 pag-aaral para sa Burkitt Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Chicago (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Nagre-recruitPhase 2

Lurie Children's Hospital-Chicago, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

366 Days – 46 Years · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Nagre-recruitPhase 3

Northwestern University, Chicago
Rush MD Anderson Cancer Center, Chicago
University of Illinois, Chicago
at 1 pa

Edad 18 hanggang 39 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT03150693

Blinatumomab Consolidation in Real World

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Northwestern University, Chicago
The University of Chicago, Chicago

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Nagre-recruitPhase 2

Northwestern University, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Nagre-recruitPhase 2

Lurie Children's Hospital-Chicago, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

365 Days · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nagre-recruitPhase 2

Lurie Children's Hospital-Chicago, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Nagre-recruitPhase 3

Lurie Children's Hospital-Chicago, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Nagre-recruitPhase 2

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Edad 7 hanggang 25 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Nagre-recruitPhase 1/2

Research Site, Chicago

Edad 12 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Nagre-recruitPhase 1/2

Research Site, Chicago

Edad 12 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Nagre-recruitPhase 2

University of Chicago Comprehensive Cancer Center, Chicago

Edad 18 hanggang 54 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Nagre-recruitPhase 1

University of Chicago Comprehensive Cancer Center, Chicago

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Nagre-recruitPhase 1/2

University of Chicago, Chicago

Edad 15 hanggang 50 · Lahat ng kasarian · Na-update Set 9, 2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Nagre-recruit

University of Chicago Medicine Comprehensive Cancer Center, Chicago

Edad 18 hanggang 50 · Lahat ng kasarian · Na-update Hun 19, 2025 · NCT06785324

Pag-aaral para sa Burkitt Lymphoma sa ibang lungsod

Iba pang pag-aaral sa Chicago

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.